We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Patented Sample Preparation Kit to Streamline DNA and RNA Sequencing Studies

By LabMedica International staff writers
Posted on 31 May 2012
Biotech and genomic researchers can now work with a patented new kit that optimizes sample preparation for DNA or RNA analysis whether performed manually or on a next generation sequencing (NGS) platform.

Rubicon Genomics, Inc. More...
(Ann Arbor, MI, USA) a well-known developer and manufacturer of sample-specific preanalytical processes to improve the performance and capabilities of DNA and RNA analytical platforms for research and clinical testing, has released the first product in its new line of the ThruPLEX sample preparation kits.

The ThruPLEX-FD kit turns sample preparation into a streamlined one-tube, three-step process without intermediate purifications, transfers, columns, or gels. The reduced steps and material transfers decrease the likelihood of experimental variability, bias, and contamination. DNA is sequencing-ready in two hours with as little as 15 minutes of hands-on time. The kit’s reagents and protocols were specifically designed for use with samples as small as 50 picograms of human DNA and can be used in plasma, FFPE (formalin-fixed, paraffin-embedded) tissue sections, cDNA, and ChIP (chromatin immunoprecipitation) DNA applications. The results are superior repair, ligation, and amplification of the genomic DNA.

ThruPLEX-FD is currently available as 48-reaction, 12-index kits for sequencing on the Illumina Inc. (San Diego, CA, USA) HiSeq, MiSeq, and Genome Analyzer instruments. Similar kits are currently being developed for additional formats and platforms.

“The accelerated adoption of NGS technology has created a demand for faster and more sensitive sample preparation,” said Dr. James Koziarz, CEO of Rubicon. “Breaking with the traditional multistep process requiring intermediate transfers and purifications, ThruPLEX uses more efficient enzymology to repair, ligate, and amplify the DNA molecules in a single tube. Our patented three-step process enables high quality sequencing of clinical samples that were previously too small or degraded to be tested. ThruPLEX-FD highlights the power of this new technology, producing accurate and reproducible results from very small amounts of fragmented DNA. We believe our ThruPLEX products will facilitate wider use of NGS and look forward to releasing additional ThruPLEX products later this year.”

Related Links:

Rubicon Genomics, Inc.
Illumina Inc.



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Nasopharyngeal Applicator
CalgiSwab 5.5" Sterile Mini-tip Calcium Alginate Nasopharyngeal Swab w/Aluminum HDLE
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.